Skip to content
  • Home
  • SeaPRwire
  • ACN Newswire
  • JCN Newswire
  • EQS Newswire
  • Latest News
  • Business
  • Finance
  • Contact Us

Search

  • Home
  • SeaPRwire
  • ACN
  • JCN
  • EQS
  • Contact
亚洲新闻、事件、深度報道

lenvima

JCN Newswire
Read More

Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

ruth 12 September
6 minutes

TOKYO and RAHWAY, N.J., Sep 12, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States […]

JCN Newswire
Read More

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial

ruth 4 August
4 minutes

TOKYO and RAHWAY, N.J., Aug 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and […]

JCN Newswire
Read More

Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

ruth 25 February
3 minutes

TOKYO and KENILWORTH, N.J., Feb 25, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and […]

JCN Newswire
Read More

Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma

ruth 20 January
3 minutes

TOKYO, Jan 20, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced […]

JCN Newswire
Read More

European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma

ruth 29 November
3 minutes

TOKYO and KENILWORTH, N.J., Nov 29, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United […]

JCN Newswire
Read More

FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)

ruth 12 August
18 minutes

TOKYO and KENILWORTH, N.J., Aug 12, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and […]

JCN Newswire
Read More

Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib

ruth 8 June
5 minutes

TOKYO and KENILWORTH, N.J., Jun 8, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. announced new investigational data from the […]

JCN Newswire
Read More

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

ruth 23 March
2 minutes

TOKYO, Mar 23, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA […]

JCN Newswire
Read More

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

ruth 15 February
4 minutes

TOKYO, Feb 15, 2021 – (JCN Newswire) – Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced […]

Links

  • YAHOO
  • NASDAQ
  • Bloomberg
  • Newswire
  • EastMud
  • AsiaEase
  • NetDace
  • PostVN
  • VOASG
  • EventPH
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
« Aug    

网站导航

  • Home
  • Latest News
  • Business
  • Finance
  • SeaPRwire
  • ACN Newswire
  • JCN Newswire
  • EQS Newswire
  • Contact Us

Search

  • Home
  • Latest News
  • Business
  • Finance
  • SeaPRwire
  • ACN Newswire
  • JCN Newswire
  • EQS Newswire
  • Contact Us
Copyright © 2020 ASEANPR.Com All rights reserved.